Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Multi-ethnic innovation helps all complexions appear clearer and more uniform
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Currently, Venkat is Lead – Market Access, India at Pfizer
Both the India and GCC entities will be operated by separate dedicated management teams
This surgery presented unique challenges, particularly due to the size of the gallbladder and the multitude of stones
Subscribe To Our Newsletter & Stay Updated
